EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report

被引：13
|
作者：
Zhou, Tong [1 ]
Zhou, Xiaoyue [1 ]
Li, Peng [1 ]
Qi, Chuang [2 ]
Ling, Yang [1 ]
机构：
[1] Soochow Univ, Dept Med Oncol, Changzhou Canc Hosp, 68 Honghe Rd, Changzhou 213032, Peoples R China
[2] 3D Med Inc, Med Dept, Shanghai 201100, Peoples R China
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷 / 12期
关键词：
RESISTANCE; CANCER;
D O I：
10.21037/jtd.2018.12.26
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：E802 / E805
页数：4
相关论文
共 50 条
  • [11] Afatinib in the treatment of brain metastases of lung cancer with one rare EGFR mutation: a two-case report
    Sun, Liwei
    Li, Bing
    Wang, Bin
    Li, Jinduo
    Li, Jing
    ANTI-CANCER DRUGS, 2022, 33 (01) : 112 - 115
  • [12] Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report
    Wu, Lige
    Fang, Cheng
    Zhao, Weiqing
    Li, Dong
    Tang, Shuxian
    Li, Xi
    Ji, Mei
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)
  • [13] Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation
    Wei, Qiang
    Zhang, Jin
    Chen, Dongsheng
    Li, Si
    Liu, Yuanhua
    LUNG CANCER, 2020, 148 : 175 - 176
  • [14] EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report
    Lu, Zhiqin
    Wang, Xia
    Luo, Yuxi
    Wei, Jianping
    Zeng, Zhimin
    Xiong, Qiang
    Cai, Jing
    Liu, Anwen
    ONCOTARGETS AND THERAPY, 2021, 14 : 2823 - 2828
  • [15] An uncommon EGFR exon 25 mutation in a patient with lung adenocarcinoma successfully treated with Afatinib
    Kunz, J.
    Christopoulos, P.
    Grosch, H.
    Kunz, J.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 109 - 109
  • [16] Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
    Huang, Jing
    Wang, Yiyin
    Zhai, Yachao
    Wang, Jin
    THORACIC CANCER, 2018, 9 (06) : 745 - 749
  • [17] Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
    Zoechbauer-Mueller, Sabine
    Kaserer, Bettina
    Prosch, Helmut
    Cseh, Agnieszka
    Solca, Flavio
    Bauer, Markus Johann
    Muellauer, Leonhard
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [18] L747P mutation in EGFR mediates the resistance to gefitinib and allosteric inhibitor by losing αC-helix flexibility
    Ohhara, Tomoko
    Fujita, Naoya
    Nishio, Makoto
    Katayama, Ryohei
    CANCER SCIENCE, 2022, 113 : 1632 - 1632
  • [19] Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P
    Guida, Annalisa
    Tassi, Valentina
    Facchinetti, Francesco
    Marchetti, Giovanni
    Caprera, Cecilia
    Ragusa, Mark
    Tiseo, Marcello
    Bracarda, Sergio
    ADVANCES IN RESPIRATORY MEDICINE, 2022, 90 (03) : 234 - 236
  • [20] A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review
    Wei, Yu
    Cui, Yueli
    Guo, Yao
    Li, Lei
    Zeng, Liang
    FRONTIERS IN ONCOLOGY, 2021, 11
12345